Innovations in the integration of advanced neuroimaging and image guided neurosurgery for the treatment of refractory brain tumors: a systematic review of clinical and functional outcomes
DOI:
https://doi.org/10.18203/2320-6012.ijrms20243420Keywords:
Neuroimaging, Image-guided surgery, Refractory brain tumors, Surgical outcomes, Intraoperative imagingAbstract
Glioblastoma is most common and aggressive types of primary brain tumors known for its resistance to treatment. Prognosis for glioblastoma (GBM) which is an aggressive primary brain tumor, is poor. Complete resection is difficult to achieve because of tumor infiltration and extent of surgical resection is crucial for increasing survival. Compared to traditional surgery, intraoperative magnetic resonance imaging (iMRI) is prescribed as a way to improve resection accuracy. In methodology, we used PubMed, Embase, and Cochrane databases while following PRISMA-compliant systematic review through October 2024. Our designed keywords were "glioblastoma," "complete resection," "iMRI," and "overall survival." Studies focusing resection and survival results and contrasted iMRI with traditional surgery were chosen and this paper was done after screening by three reviewers. Results show fifteen studies with 2,299 glioblastoma patients were reviewed and results revealed iMRI improved the complete resection rate (68% versus 44%, OR: 2.4, p<0.001). Overall survival was higher in iMRI group (18.6 versus 13.7 months, HR: 0.76, p=0.005) and progression-free survival also improved (10.3 versus 7.5 months, HR: 0.79, p=0.004). We conclude that among patients with glioblastoma, intraoperative MRI is linked to a considerable increase in overall survival and total resection rates. The significant benefit of using iMRI in surgical practice is that it can be applied to aggressive tumors with difficult margins, and cost-effectiveness and long-term results should be the main topics of future studies.
Metrics
References
Anjum K, Shagufta BI, Abbas SQ, Patel S, Khan I, Shah SA, et al. Current status and future therapeutic perspectives of glioblastoma multiforme (GBM) therapy: A review. Biomed Pharmacother. 2017;92:681-9.
The Brain Tumour Charity. Glioblastoma prognosis | Survival Rates. The Brain Tumour Charity. 2024. Available at: https://www.thebraintumourcharity. org/brain-tumour-diagnosis-treatment/types-of-brain-tumour-adult/glioblastoma/glioblastoma-prognosis/. Accessed on 12 May 2024.
Carrano A, Juarez JJ, Incontri D, Ibarra A, Cazares HG. Sex-Specific differences in glioblastoma. Cells. 2021;10(7):1783.
Bradley WG. Achieving gross total resection of brain tumors: amaative MR imaging can make a big difference. Am J Neuroradiol. 2002;23(3):348-9.
Kuhnt D, Becker A, Ganslandt O, Bauer M, Buchfelder M, Nimsky C. Correlation of the extent of tumor volume resection and patient survival in surgery of glioblastoma multiforme with high-field intraoperative MRI guidance. Neuro-oncology. 2011;13(12):1339-48.
Roder C, Bisdas S, Ebner FH, Honegger J, Nägele T, Ernemann U, et al. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol. 2014;40(3):297-304.
Hu S, Kang H, Baek Y, El Fakhri G, Kuang A, Choi HS. Real‐time imaging of brain tumor for image‐guided surgery. Adv Healthc Mat. 2018;7(16):1800066.
Bernstock JD, Gary SE, Klinger N, Valdes PA, Ibn Essayed W, Olsen HE, et al. Standard clinical approaches and emerging modalities for glioblastoma imaging. Neuro-Oncol Adv. 2022;4(1):vdac080.
Hu LS, Eschbacher JM, Heiserman JE, Dueck AC, Shapiro WR, Liu S, et al. Reevaluating the imaging definition of tumor progression: perfusion MRI quantifies recurrent glioblastoma tumor fraction, pseudoprogression, and radiation necrosis to predict survival. Neuro-oncology. 2012;14(7):919-30.
Seker-Polat F, Pinarbasi Degirmenci N, Solaroglu I, Bagci-Onder T. Tumor cell infiltration into the brain in glioblastoma: from mechanisms to clinical perspectives. Cancers. 2022;14(2):443.
Roder C, Bisdas S, Ebner FH, Honegger J, Nägele T, Ernemann U, et al. Maximizing the extent of resection and survival benefit of patients in glioblastoma surgery: high-field iMRI versus conventional and 5-ALA-assisted surgery. Eur J Surg Oncol. 2014;40(3):297-304.
Carmell N. Identification of Novel Targets to Augment Temozolomide Potency in Glioblastoma (Doctoral dissertation, University of Sheffield). 2018.
Kubben PL, ter Meulen KJ, Schijns OE, ter Laak-Poort MP, van Overbeeke JJ, van Santbrink H. Intraoperative MRI-guided resection of glioblastoma multiforme: a systematic review. Lancet Oncol. 2011;12(11):1062-70.
Wu JS, Gong X, Song YY, Zhuang DX, Yao CJ, Qiu TM, et al. 3.0-T intraoperative magnetic resonance imaging-guided resection in cerebral glioma surgery: interim analysis of a prospective, randomized, triple-blind, parallel-controlled trial. Neurosurgery. 2014;61:145-54.
Mislow JM, Golby AJ, Black PM. Origins of intraoperative MRI. Neurosurg Clin. 2009;20(2):137-46.
Rao G. Intraoperative MRI and maximizing extent of resection. Neurosurg Clin. 2017;28(4):477-85.
Gerritsen JKW, Broekman MLD, De Vleeschouwer S, Schucht P, Nahed BV, Berger MS, et al. Safe surgery for glioblastoma: Recent advances and modern challenges. Neuro-Oncol Pract. 2022;9(5):364-79.
Pichardo-Rojas PS, Angulo-Lozano JC, Alvarez-Castro JA, Vázquez-Alva D, Osuna-Lau RA, Choque-Ayala LC, et al. Intraoperative Magnetic Resonance Imaging (MRI)-Guided Resection of Glioblastoma: A Meta-Analysis of 1,847 Patients. World Neurosurg. 2024;182:e807-22.
Bernstock JD, Gary SE, Klinger N, Valdes PA, Ibn Essayed W, Olsen HE, et al. Standard clinical approaches and emerging modalities for glioblastoma imaging. Neuro-Oncol Adv. 2022;4(1):vdac080.
Chourmouzi D, Papadopoulou E, Marias K, Drevelegas A. Imaging of brain tumors. Surg Oncol Clin. 2014;23(4):629-84.
Rudie JD, Rauschecker AM, Bryan RN, Davatzikos C, Mohan S. Emerging applications of artificial intelligence in neuro-oncology. Radiology. 2019;290(3):607-18.
Lee H, Guo Y, Ross JL, Schoen Jr S, Degertekin FL, Arvanitis C. Spatially targeted brain cancer immunotherapy with closed-loop controlled focused ultrasound and immune checkpoint blockade. Sci Adv. 2022;8(46):eadd2288.
Wu M, Zhang Y, Zhang Y, Liu Y, Wu M, Ye Z. Imaging-based biomarkers for predicting and evaluating cancer immunotherapy response. Radiol Imag Cancer. 2019;1(2):e190031.
Ottobrini L, Martelli C, Lucignani G. Optical Imaging Agents. Molecular Imaging. Academic Press. 2021;603-25.
Bu L, Shen B, Cheng Z. Fluorescent imaging of cancerous tissues for targeted surgery. Adv Drug Deliv Rev. 2014;76:21-38.
Zhang W, Ille S, Schwendner M, Wiestler B, Meyer B, Krieg SM. The Impact of ioMRI on Glioblastoma Resection and Clinical Outcomes in a State-of-the-Art Neuro-Oncological Setup. Cancers (Basel). 2023;15(14):3563.
Shah AS, Sylvester PT, Yahanda AT, Vellimana AK, Dunn GP, Evans J, et al. Intraoperative MRI for newly diagnosed supratentorial glioblastoma: a multicenter-registry comparative study to conventional surgery. J Neurosurg. 2020;135(2):505-14.
Löfgren D, Valachis A, Olivecrona M. Risk for morbidity and mortality after neurosurgery in older patients with high grade gliomas - a retrospective population based study. BMC Geriatr. 2022;22(1):805.
Lo YT, Lee H, Shui C, Lamba N, Korde R, Devi S, et al. Intraoperative Magnetic Resonance Imaging for Low-Grade and High-Grade Gliomas: What Is the Evidence? A Meta-Analysis. World Neurosurg. 2021;149:232-43.
Jin W, Fatehi M, Abhishek K, Mallya M, Toyota B, Hamarneh G. Artificial intelligence in glioma imaging: challenges and advances. J Neural Engineering. 2020;17(2):021002.
